Skip to content

CONEXUS PHARMA

Absorbed by REGON on 30-01-2018 KBO/BCE: BE 0538.611.801 subsidiary of REGON

Last board

No change since 2014
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“De vennootschap wordt in en buiten rechte geldig vertegenwoordigd: - hetzij door één gedelegeerd bestuurder; - hetzij door twee bestuurders…”
deed of 24-09-2013

Office holders in the KBO →

Mandates through the years

5 names

Director

Director

Managing director

Director

Managing director
Earlierend not dated
Mandates as a list
    • Director, appointed by deed of 24-09-2013, last mentioned in 2014
    • Director, appointed by deed of 24-09-2013, last mentioned in 2014
    • Director, appointed by deed of 24-02-2014, last mentioned in 2014
    • Managing director, appointed by deed of 24-02-2014, last mentioned in 2014
    • Director, appointed by deed of 24-09-2013, last mentioned in 2014
    • Director, appointed by deed of 24-09-2013, last mentioned in 2013
    • Managing director, appointed by deed of 24-09-2013, last mentioned in 2013

Control

Parent
Equity €2.5m
Profit €52,477 in 2025 (profit €36,358 in 2024)
100%
This company
CONEXUS PHARMA
Equity €14,759
Loss €1,839 in 2016

Capital

Capital
€61,500
Source
2016 annual accounts

Articles of association

DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 24-09-2013 (in Dutch)
Board ruleThese rules set how the board is made up, meets and takes decisions.
Term of at most 6 years
deed of 24-09-2013 (in Dutch)
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Second Monday of May at 10:00
deed of 24-02-2014 (in Dutch)

Capital transactions

Shareholders according to the deeds
Stated in the deed deed of 30-01-2018 ↗
  • all shares
Stated in the deed deed of 15-09-2017 ↗
  • all shares

Next steps